{"corpus_id":8824506,"paper_sha":"21adca045b6025abfe39972e356bd0a44d00ecbd","doi":"10.4081/REUMATISMO.2006.191","arxiv_id":null,"pmid":17013435,"pmcid":null,"mag_id":2342370980,"dblp_id":null,"acl_id":null,"title":"[Occupational therapy in rheumatoid arthritis: short term prospective study in patients treated with anti-TNF-alpha drugs].","year":2011,"publication_date":"2011-09-01","venue":"Reumatismo","journal":{"name":"Reumatismo","pages":"\n          191-8\n        ","volume":"58 3"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","Study","ClinicalTrial","Review"],"pubmed_pub_types":["Comparative Study","Controlled Clinical Trial","Evaluation Study","Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":25,"citation_count":5,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Activities of Daily Living","mj":false,"ui":"D000203"},{"d":"Adalimumab","mj":false,"ui":"D000068879"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Anti-Inflammatory Agents","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000893"},{"d":"Anti-Inflammatory Agents, Non-Steroidal","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000894"},{"d":"Antibodies, Monoclonal","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000911"},{"d":"Antibodies, Monoclonal, Humanized","mj":false,"ui":"D061067"},{"d":"Antirheumatic Agents","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D018501"},{"d":"Arthritis, Rheumatoid","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"},{"q":"diagnosis","mj":false,"ui":"Q000175"},{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"rehabilitation","mj":true,"ui":"Q000534"}],"ui":"D001172"},{"d":"Blood Sedimentation","mj":false,"ui":"D001799"},{"d":"C-Reactive Protein","mj":false,"qs":[{"q":"analysis","mj":false,"ui":"Q000032"}],"ui":"D002097"},{"d":"Cortisone","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D003348"},{"d":"Data Interpretation, Statistical","mj":false,"ui":"D003627"},{"d":"Etanercept","mj":false,"ui":"D000068800"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Health Status","mj":false,"ui":"D006304"},{"d":"Health Surveys","mj":false,"ui":"D006306"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Immunoglobulin G","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D007074"},{"d":"Infliximab","mj":false,"ui":"D000069285"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Occupational Therapy","mj":true,"ui":"D009788"},{"d":"Patient Compliance","mj":false,"ui":"D010349"},{"d":"Prospective Studies","mj":false,"ui":"D011446"},{"d":"Receptors, Tumor Necrosis Factor","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D018124"},{"d":"Socioeconomic Factors","mj":false,"ui":"D012959"},{"d":"Surveys and Questionnaires","mj":false,"ui":"D011795"},{"d":"Time Factors","mj":false,"ui":"D013997"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"Tumor Necrosis Factor-alpha","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":true,"ui":"Q000037"}],"ui":"D014409"}],"chemicals":[{"n":"Anti-Inflammatory Agents","ui":"D000893","reg":"0"},{"n":"Anti-Inflammatory Agents, Non-Steroidal","ui":"D000894","reg":"0"},{"n":"Antibodies, Monoclonal","ui":"D000911","reg":"0"},{"n":"Antibodies, Monoclonal, Humanized","ui":"D061067","reg":"0"},{"n":"Antirheumatic Agents","ui":"D018501","reg":"0"},{"n":"Immunoglobulin G","ui":"D007074","reg":"0"},{"n":"Receptors, Tumor Necrosis Factor","ui":"D018124","reg":"0"},{"n":"Tumor Necrosis Factor-alpha","ui":"D014409","reg":"0"},{"n":"C-Reactive Protein","ui":"D002097","reg":"9007-41-4"},{"n":"Infliximab","ui":"D000069285","reg":"B72HH48FLU"},{"n":"Adalimumab","ui":"D000068879","reg":"FYS6T7F842"},{"n":"Etanercept","ui":"D000068800","reg":"OP401G7OJC"},{"n":"Cortisone","ui":"D003348","reg":"V27W9254FZ"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.reumatismo.org/index.php/reuma/article/download/reumatismo.2006.191/258","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/21adca045b6025abfe39972e356bd0a44d00ecbd","s2_open_access_license":"CCBYNC","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"OBJECTIVE\nTo assess the effect of occupational therapy (OT) in rheumatoid arthritis (RA) patients treated with anti-TNF-alpha drugs in a short-term open controlled prospective study.\n\n\nMETHODS\n31 RA subjects [(M/F=5/26; mean age= 56 (range=28-73) years; mean disease duration= 165 (range =15-432) months], treated with anti- TNF-alpha drugs, were allocated to OT (n=15) or control (n=16) group. We evaluated at entry and 12 weeks the following outcome parameters including Health Assessment Questionnaire (HAQ), Short-Form Health Survey (SF-36), Global Health (GH), Ritchie index, number of swollen or tender joints, pain, patient and physician disease activity, Disease Activity Score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein CRP) and the correct adherence to items regarding activity daily living (ADL).\n\n\nRESULTS\nAt baseline, OT and control group had similar demographic and clinical features. After 12 weeks, the changes from baseline of main outcome parameters were not significantly different between the two groups. After 12 weeks, in 7 out of 11 items regarding ADL, the percentage of patients showing a correct adherence was significantly increased in OT group only. Moreover at the end of the study, the OT group showed a correct adherence to 8 out of 11 ADL items in an higher percentage of patients respect to the control group.\n\n\nCONCLUSION\nOur study sustains that OT improves self-management but not main parameters of disease activity or functional capacity. Nevertheless educational intervention should be considered as a useful tool in conjunction with pharmacological treatment.","claims":[{"public_id":"cl_f4add16cc10b947fad7895ca5b07ded5","status":"active","text":"At the end of the study, the occupational therapy group showed correct adherence to 8 of 11 activity daily living items in a higher percentage of patients than the control group.","confidence":0.93,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_f4add16cc10b947fad7895ca5b07ded5"},{"public_id":"cl_e0b3b76b2b04b62eabc133bac06ffab4","status":"active","text":"Changes from baseline in the main outcome parameters after 12 weeks were not significantly different between the occupational therapy and control groups.","confidence":0.9,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_e0b3b76b2b04b62eabc133bac06ffab4"},{"public_id":"cl_4b5ac256d43b0234573f9d4bf0a63831","status":"active","text":"Correct adherence increased significantly in the occupational therapy group for 7 of 11 activity daily living items after 12 weeks.","confidence":0.94,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_4b5ac256d43b0234573f9d4bf0a63831"},{"public_id":"cl_32b51490efb132ce95d7fb34a23d71f6","status":"active","text":"Occupational therapy improved self-management in rheumatoid arthritis patients treated with anti-TNF-alpha drugs over 12 weeks.","confidence":0.89,"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_32b51490efb132ce95d7fb34a23d71f6"}],"concepts":[{"public_id":"co_02488e24f411ef9374dd9698884a6a72","status":"active","name":"correct adherence","description":"A measure of whether patients properly followed items regarding activity daily living.","types":["behavioral outcome"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_02488e24f411ef9374dd9698884a6a72"},{"public_id":"co_16a0f538d56e8f63a6d9fc0e286c8ed9","status":"active","name":"activity daily living items","description":"Items concerning daily living activities used to assess patients' correct adherence.","types":["adherence items"],"aliases":["ADL"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_16a0f538d56e8f63a6d9fc0e286c8ed9"},{"public_id":"co_1c5b6d54482c0ad44806ed755386324a","status":"active","name":"Disease Activity Score","description":"A disease activity measure evaluated among the rheumatoid arthritis outcome parameters.","types":["disease activity measure"],"aliases":["DAS28"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_1c5b6d54482c0ad44806ed755386324a"},{"public_id":"co_30b767dfce126cd9d894e211f5573acf","status":"active","name":"main outcome parameters","description":"Clinical, functional, quality-of-life, inflammatory, and disease activity measures evaluated at entry and 12 weeks.","types":["outcome measures"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_30b767dfce126cd9d894e211f5573acf"},{"public_id":"co_574b0d6ce87e169c1c0f71b0b234a821","status":"active","name":"Health Assessment Questionnaire","description":"A functional assessment measure evaluated as an outcome parameter in the rheumatoid arthritis patients.","types":["assessment instrument"],"aliases":["HAQ"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_574b0d6ce87e169c1c0f71b0b234a821"},{"public_id":"co_5f359200a68a275ae0cd107b15a5cf9c","status":"active","name":"control group","description":"The comparison group of rheumatoid arthritis patients that was not allocated to occupational therapy.","types":["comparison group"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_5f359200a68a275ae0cd107b15a5cf9c"},{"public_id":"co_5f729a050c13e615491f9a02056c5a8b","status":"active","name":"rheumatoid arthritis patients","description":"Patients with rheumatoid arthritis who were receiving anti-TNF-alpha drug treatment in the study population.","types":["population"],"aliases":["RA subjects"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_5f729a050c13e615491f9a02056c5a8b"},{"public_id":"co_727c3fe337705c960f2fa1c439246d11","status":"active","name":"occupational therapy group","description":"The group of rheumatoid arthritis patients allocated to receive occupational therapy.","types":["intervention group"],"aliases":["OT group"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_727c3fe337705c960f2fa1c439246d11"},{"public_id":"co_765a92c6fa37b8bbb95a622f28a75f47","status":"active","name":"12 weeks","description":"The short-term follow-up interval at which outcomes were reassessed after study entry.","types":["time point"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_765a92c6fa37b8bbb95a622f28a75f47"},{"public_id":"co_a0ce4d6a435f9a6565c2ffcde607a92b","status":"active","name":"anti-TNF-alpha drugs","description":"The pharmacological treatment being received by all enrolled rheumatoid arthritis subjects.","types":["treatment"],"aliases":[],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_a0ce4d6a435f9a6565c2ffcde607a92b"},{"public_id":"co_f36b19c3552dc3e0981beac9a1738fb7","status":"active","name":"occupational therapy","description":"A non-pharmacological intervention allocated to one group of rheumatoid arthritis patients in this short-term prospective study.","types":["intervention"],"aliases":["OT"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_f36b19c3552dc3e0981beac9a1738fb7"}],"external_ids":{"DOI":"10.4081/REUMATISMO.2006.191","ArXiv":null,"PubMed":17013435,"PubMedCentral":null,"MAG":2342370980,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.reumatismo.org/index.php/reuma/article/download/reumatismo.2006.191/258","landing_url":"https://www.semanticscholar.org/paper/21adca045b6025abfe39972e356bd0a44d00ecbd","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNC","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631645,"paper_uid":"dafc2506-8bf6-45c7-bed1-92ef1136062f","canonical_identity":{"paper_id":631645,"paper_uid":"dafc2506-8bf6-45c7-bed1-92ef1136062f","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/8824506"}